Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Carexil 20mg modified-release tablets
0407020ADBDACAG
|
Carexil | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Carexil 40mg modified-release tablets
0407020ADBDADAH
|
Carexil | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Carexil 5mg modified-release tablets
0407020ADBDAAAK
|
Carexil | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Carexil 80mg modified-release tablets
0407020ADBDAEAI
|
Carexil | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Dolocodon PR 10mg tablets
0407020ADBIADAF
|
Dolocodon PR | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Dolocodon PR 20mg tablets
0407020ADBIAAAG
|
Dolocodon PR | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Dolocodon PR 40mg tablets
0407020ADBIABAH
|
Dolocodon PR | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Dolocodon PR 5mg tablets
0407020ADBIACAK
|
Dolocodon PR | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 10mg modified-release tablets
0407020ADBPABAF
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 20mg modified-release tablets
0407020ADBPACAG
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 30mg modified-release tablets
0407020ADBPADAR
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 40mg modified-release tablets
0407020ADBPAEAH
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 5mg modified-release tablets
0407020ADBPAAAK
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 60mg modified-release tablets
0407020ADBPAFAQ
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Leveraxo 80mg modified-release tablets
0407020ADBPAGAI
|
Leveraxo | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Onexila XL 80mg tablets
0407020ADBQADAI
|
Onexila XL | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 10mg modified-release tablets (Actavis)
0407020ADBFAGAF
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 20mg modified-release tablets (Actavis)
0407020ADBFAHAG
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 40mg modified-release tablets (Actavis)
0407020ADBFAIAH
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 5mg modified-release tablets (Actavis)
0407020ADBFAFAK
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Oxylan 80mg modified-release tablets (Actavis)
0407020ADBFAJAI
|
Oxylan | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Zomestine 10mg modified-release tablets
0407020ADBNADAF
|
Zomestine | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Zomestine 20mg modified-release tablets
0407020ADBNAEAG
|
Zomestine | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Zomestine 40mg modified-release tablets
0407020ADBNABAH
|
Zomestine | Oxycodone hydrochloride | Central Nervous System | No data available |
|
Zomestine 5mg modified-release tablets
0407020ADBNACAK
|
Zomestine | Oxycodone hydrochloride | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.